© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Fabienne Mcclanahan, MD | Authors
Articles
Immunotherapeutic Approaches Have the Potential to Brighten the Future Not Only for Patients With del(17p13.1), but for All CLL Patients
November 15, 2012
Most cases the clinical management of CLL patients with del(17p13.1) poses enormous challenges, and patients should be included in clinical trials whenever possible. However, there are a number of promising novel drugs and immunotherapy strategies under investigation.